Single-center phase 2 trial of first-line bevacizumab plus tislelizumab and nab-paclitaxel for metastatic triple-negative breast cancer

The optimal first-line therapy for metastatic triple-negative breast cancer (mTNBC) is not clear. The phase 2 BETINA trial, at Sun Yat-sen University Cancer Center (Guangzhou, China), evaluated the combination of anti-angiogenic bevacizumab, anti-PD-1 tislelizumab, and nab-paclitaxel chemotherapy for previously untreated mTNBC. The figure shows the efficacy outcomes. The objective response rate (primary endpoint) was 73.3% and the disease control rate was 90.0%, while the median progression-free survival was 6.0 months and the median overall survival was 19.8 months. There were no new safety signals. Common treatment-related adverse events were peripheral sensory neuropathy (83.3%), dyspepsia (70.0%), anemia (70.0%), leukocytopenia (66.7%), and pruritus (53.3%), with hypothyroidism (30.0%) as most frequent immune-related adverse event. The authors conclude that BETINA demonstrated promising activity and favorable tolerability among patients with previously untreated mTNBC.